Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Savings from Generic Use Increase Sharply from FY2013 through FY2015: MHLW Estimate
April 27, 2017
- New LDP Lawmaker Group on Generics to Draw Up Proposal for 2017 Fiscal Blueprint
April 26, 2017
- Non-Partisan Lawmaker Group on Cooperation with WHO Set Up, Eyeing Asia Pacific Region Congress in Japan this Summer
April 26, 2017
- Me-Too Drugs in Jeopardy? CEFP Working Group Pushes Rigid Drug Selection for Innovation Premium
April 26, 2017
- LDP Health Panel to Compile Resolution on Drug Pricing
April 25, 2017
- Drug Pricing Is Internal Affairs Not Subject to Bilateral Talks: Minister
April 25, 2017
- Apply GDP to Cash-and-Carry Dealers Too: MHLW Panel Members
April 24, 2017
- MHLW Committee Backs Approval of Mundipharma’s PTCL Med Pralatrexate
April 24, 2017
- Commerce Secretary Ross Made No Specific Demand on Drug Pricing: Shiozaki
April 24, 2017
- Negative Opinions Exist for Use of Cost Effective Assessments in Drug Listing: MHLW Official
April 24, 2017
- Sakigake Fast-Track Designation Given to Aducanumab, 4 Other Products
April 24, 2017
- MHLW Panel OKs 2-Year Extension of Reexamination Period for E Keppra due to Development of Dosage for Children Younger than 4
April 24, 2017
- MHLW to Examine Bayer Issue from Pharmaceutical Law Viewpoint without Prejudgment: Bureau Chief
April 21, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
- MOF Puts June-End Generic Share at Around 65%, Just Shy of Mid-Year 70% Target
April 21, 2017
- MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
- MHLW Cautions on Incidences of Multiple Vertebral Body Fractures after Discontinuation of Pralia Treatment
April 21, 2017
- MHLW Re-Cautions Use of Sleep/Anxiolytic/Epilepsy Agents Containing 44 APIs
April 19, 2017
- Optimal Use Guidelines Issued for Opdivo Use in RCC, Hodgkin’s Lymphoma
April 19, 2017
- New MHLW Panel Starts Discussions on Proper Drug Use Guidelines for Elderly; Final Report Expected by End of FY2018
April 19, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…